Eurofins Technologies Launches New SENSIStrip Allergen Product Range: Quickly Detects Allergens That Must Be Labeled On Packaged Food

December 14, 2020

Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces the launch of the new SENSIStrip Allergen product range, which quickly detects allergens that must be labeled on packaged food products.

Managing food allergies usually means completely eliminating the allergen from one’s diet. To achieve this, consumers rely on clear labeling and traceability throughout the entire food production process, from raw material to the final product.

SENSIStrip Allergen kits are based on the concept of an immunoassay, an easy-to-use and quick method that requires only a few minutes of incubation time. This enables adequate allergen control at different stages of the food manufacturing process, across food matrices, rinse water, and equipment.

With low detection limits and accessibility (the kit does not require the expertise of highly-qualified staff to operate it), the SENSIStrip Allergen kits are the perfect tool to control potential cross-contamination with food allergens, allowing for quick screening of raw materials, the production process, and the final product. This avoids the external analyses and thus considerably reduces the time taken to release a food product batch to market.

The kits are provided with all the necessary and ready-to-use material to perform analysis across 20 individual tests per kit, on food matrices or environmental samples. In addition, an evaluation card is included to enable a semi-quantitative result, based on the intensity of the test line on the strip.

This new product range is a key component of Eurofins Technologies’ food allergen management and cleaning control monitoring solutions which, together with the comprehensive line of SENSISpec ELISA assays for allergen detection, demonstrate Eurofins Technologies’ commitment to providing high-quality test methods for food safety customers.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version